ACLX News and Press, Arcellx Inc. From 02/02/23

Arcellx to Participate in Upcoming Investor Conferences PR Newswire REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patien...

Gilead Sciences' ( NASDAQ: GILD ) Kite unit and Arcellx ( NASDAQ: ACLX ) have finalized a collaboration for the further development of CART-ddBCMA, the latter company's lead treatment for relapsed or refractory multiple myeloma. The T-cell therapy, currently in phase 2, will b...

Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatme...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead. Arcellx goes up against Johnson & Johnson's formidable carvykti, but now it has help. Arcellx, Inc. ( ACLX ) is up 83% since my bullish coverage f...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it’s teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ). Together,...

Arcellx ( NASDAQ: ACLX ) on Friday said it would co-develop and co-commercialize its lead late-stage product candidate CART-ddBCMA for the treatment of multiple myeloma with Kite, a Gilead Sciences ( NASDAQ: GILD ) company. Under the global strategic collaboration, ACLX wi...

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress PR Newswire -- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses o...

-- Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing -- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to ...